Skip to main content
. 2019 Oct 10;18(6):5793–5800. doi: 10.3892/ol.2019.10975

Figure 2.

Figure 2.

Effect of celecoxib on oral squamous cell carcinoma tumor growth with/without LPS-treated HSC-3 ×enografts. (A) Representative tumor images 28 days after treatment in each group. (B) Mean tumor volumes ± standard deviation. The tumor volumes decreased in the celecoxib-treated and LPS + celecoxib-treated groups compared with the control and LPS-treated groups. (C) Mouse body weights. There were no significant differences in body weight between the four treatment groups. **P<0.01 vs. control or LPS-treated group. LPS, lipopolysaccharide.